Efficacy and safety of 1064-nm fractional picosecond laser for the treatment of postmastectomy scars in transgender men: A randomized controlled trial

IF 2.2 3区医学 Q2 DERMATOLOGY

Lasers in Surgery and Medicine Pub Date : 2024-03-04 DOI:10.1002/lsm.23775

Suthinee Rutnin MD, Tanat Yongpisarn MD, Nawara Sakpuwadol MD, Amornrut Namasondhi MD, Cherrin Pomsoong MD, Teerapong Rattananukrom MD, MSc, Kunlawat Thadanipon MD

{"title":"Efficacy and safety of 1064-nm fractional picosecond laser for the treatment of postmastectomy scars in transgender men: A randomized controlled trial","authors":"Suthinee Rutnin MD, Tanat Yongpisarn MD, Nawara Sakpuwadol MD, Amornrut Namasondhi MD, Cherrin Pomsoong MD, Teerapong Rattananukrom MD, MSc, Kunlawat Thadanipon MD","doi":"10.1002/lsm.23775","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>Subcutaneous mastectomy is a crucial component of gender affirmation therapy for transgender men (TM), but the scars that result from this procedure can frequently impair their quality of life. This study aimed to assess the efficacy and safety of 1064-nm fractional picosecond laser (FxPico) treatment for hypertrophic and atrophic postmastectomy scars in TM.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Twenty-two patients with a total of 35 pairs of bilateral symmetric mastectomy scars were enrolled. One of each pair of symmetric scars was randomly assigned to receive four FxPico treatments at 4-week intervals. All scars were evaluated using the modified Vancouver Scar Scale (mVSS) and three-dimensional imaging for scar roughness, melanin index, and hemoglobin index before each treatment session and at 1, 3, and 6 months following the last treatment. Additionally, participant-rated scar satisfaction (PSS) and scar improvement (Global Assessment Score, GAS), as well as adverse events were recorded.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>During the 6-month follow-up period after the end of laser treatment sessions, the treated scars showed significant reductions in the mVSS compared to the untreated controls (<i>p</i> < 0.001), whereas the melanin index and hemoglobin index were not significantly different. Subgroup analysis of hypertrophic scars demonstrated statistically significant reductions in mVSS at 1 (<i>p</i> = 0.003) and 3 months (<i>p</i> = 0.041) after the end of laser treatments. PSS was significantly higher on the laser-treated scars than the controls (<i>p</i> = 0.008), and a participant-rated GAS of 2.95 ± 0.65 was found. There were no serious adverse events reported.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>1064-nm FxPico could be utilized to treat mastectomy scars among TM, particularly the hypertrophic type.</p>\n </section>\n </div>","PeriodicalId":17961,"journal":{"name":"Lasers in Surgery and Medicine","volume":"56 4","pages":"337-345"},"PeriodicalIF":2.2000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lasers in Surgery and Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/lsm.23775","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Subcutaneous mastectomy is a crucial component of gender affirmation therapy for transgender men (TM), but the scars that result from this procedure can frequently impair their quality of life. This study aimed to assess the efficacy and safety of 1064-nm fractional picosecond laser (FxPico) treatment for hypertrophic and atrophic postmastectomy scars in TM.

Methods

Twenty-two patients with a total of 35 pairs of bilateral symmetric mastectomy scars were enrolled. One of each pair of symmetric scars was randomly assigned to receive four FxPico treatments at 4-week intervals. All scars were evaluated using the modified Vancouver Scar Scale (mVSS) and three-dimensional imaging for scar roughness, melanin index, and hemoglobin index before each treatment session and at 1, 3, and 6 months following the last treatment. Additionally, participant-rated scar satisfaction (PSS) and scar improvement (Global Assessment Score, GAS), as well as adverse events were recorded.

Results

During the 6-month follow-up period after the end of laser treatment sessions, the treated scars showed significant reductions in the mVSS compared to the untreated controls (p < 0.001), whereas the melanin index and hemoglobin index were not significantly different. Subgroup analysis of hypertrophic scars demonstrated statistically significant reductions in mVSS at 1 (p = 0.003) and 3 months (p = 0.041) after the end of laser treatments. PSS was significantly higher on the laser-treated scars than the controls (p = 0.008), and a participant-rated GAS of 2.95 ± 0.65 was found. There were no serious adverse events reported.

Conclusions

1064-nm FxPico could be utilized to treat mastectomy scars among TM, particularly the hypertrophic type.

查看原文本刊更多论文

1064 纳米点阵皮秒激光治疗变性男性乳房切除术后疤痕的有效性和安全性：随机对照试验。

目的：皮下乳房切除术是变性男性（TM）性别确认疗法的重要组成部分，但手术后留下的疤痕经常会影响他们的生活质量。本研究旨在评估 1064 纳米点阵皮秒激光（FxPico）治疗变性人乳房切除术后增生性和萎缩性疤痕的有效性和安全性：22名患者共35对双侧对称乳房切除术后疤痕。每对对称疤痕中的一人被随机分配接受四次 FxPico 治疗，每次间隔四周。在每次治疗前和最后一次治疗后的 1、3 和 6 个月，使用改良温哥华疤痕量表 (mVSS) 和三维成像技术对所有疤痕的粗糙度、黑色素指数和血红蛋白指数进行评估。此外，还记录了参与者的疤痕满意度（PSS）和疤痕改善情况（全球评估分数，GAS）以及不良反应：结果：在激光治疗疗程结束后的 6 个月随访期间，与未治疗的对照组相比，治疗后疤痕的 mVSS 显著降低（P 结论：治疗后疤痕的 mVSS 显著降低：1064 纳米 FxPico 可用于治疗 TM 中的乳房切除术疤痕，尤其是增生型疤痕。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lasers in Surgery and Medicine 医学-外科

CiteScore

5.40

自引率

12.50%

发文量

119

审稿时长

1 months

期刊介绍： Lasers in Surgery and Medicine publishes the highest quality research and clinical manuscripts in areas relating to the use of lasers in medicine and biology. The journal publishes basic and clinical studies on the therapeutic and diagnostic use of lasers in all the surgical and medical specialties. Contributions regarding clinical trials, new therapeutic techniques or instrumentation, laser biophysics and bioengineering, photobiology and photochemistry, outcomes research, cost-effectiveness, and other aspects of biomedicine are welcome. Using a process of rigorous yet rapid review of submitted manuscripts, findings of high scientific and medical interest are published with a minimum delay.